A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
Tekijät: Zhang Jiahui, Ji Cheng, Zhang Hongbo, Shi Hui, Mao Fei, Qian Hui, Xu Wenrong, Wang Dongqing, Pan Jianming, Fang Xinjian, Santos Helder A., Zhang Xu
Kustantaja: AMER ASSOC ADVANCEMENT SCIENCE
Julkaisuvuosi: 2022
Journal: Science Advances
Tietokannassa oleva lehden nimi: SCIENCE ADVANCES
Lehden akronyymi: SCI ADV
Artikkelin numero: eabj8207
Vuosikerta: 8
Numero: 2
Sivujen määrä: 13
ISSN: 2375-2548
DOI: https://doi.org/10.1126/sciadv.abj8207
Verkko-osoite: https://www.science.org/doi/10.1126/sciadv.abj8207
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/174776743
Neutrophils are the most abundant innate immune cells in human circulation; however, their derived exosomes have been rarely studied for tumor treatment. Here, we reported that exosomes from neutrophils (N-Ex) induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signaling pathway. In addition, we decorated N-Ex with superparamagnetic iron oxide nanoparticles ( SPIONs) to achieve higher tumor-targeting therapeutic effect. We further fabricated exosome-like nanovesicles from neutrophils (NNVs) at high yield. Compared with liposome-loaded doxorubicin (DOX) and natural NNVs, DOX-loaded NNVs show an improved inhibition of tumor cell proliferation. Moreover, DOX-loaded, SPION-decorated NNVs selectively accumulate at the tumor sites under an external magnetic field, effectively restraining tumor growth and extensively prolonging the survival rate in mice. Overall, a simple and effective method to engineer N-Ex and NNVs at clinical applicable scale was developed, which enables the efficient and safe drug delivery for targeted and combined tumor therapy.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
